[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578380":3},{"organization":4,"armGroups":7,"interventions":39,"overallOfficials":52,"centralContacts":56,"locations":61,"responsibleParty":255,"collaborators":257,"id":260,"slug":261,"hasResults":262,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":45,"eligibilityCriteria":266,"healthyVolunteers":262,"sex":267,"minAge":268,"maxAge":45,"enrollmentInfo":269,"targetDuration":45,"studyType":272,"phases":273,"briefSummary":276,"conditions":277,"keywords":285,"overallStatus":64,"whyStopped":45,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":299},{"fullName":5,"class":6},"Tango Therapeutics, Inc.","INDUSTRY",[8,15,19,23,27,31,35],{"label":9,"type":10,"description":11,"interventionNames":12},"Single Agent and Combination Dose Escalation","EXPERIMENTAL","Solid tumor participants with confirmed MTAP loss will receive escalating doses of TNG456 single agent and in combination with abemaciclib to estimate the MTD",[13,14],"Drug: TNG456","Drug: abemaciclib",{"label":16,"type":10,"description":17,"interventionNames":18},"NSCLC Single Agent Dose Expansion","NSCLC (squamous and non squamous) participants with confirmed MTAP loss will receive TNG456 at the identified RP2D(s)",[13],{"label":20,"type":10,"description":21,"interventionNames":22},"GBM Single Agent Dose Expansion","GBM participants with confirmed MTAP loss will receive TNG456 at the identified RP2D(s)",[13],{"label":24,"type":10,"description":25,"interventionNames":26},"Tumor Agnostic Single Agent Dose Expansion","Patients with specific solid tumor types that have a confirmed MTAP loss will receive TNG456 at the identified RP2D(s)",[13],{"label":28,"type":10,"description":29,"interventionNames":30},"NSCLC Combination Expansion","NSCLC (squamous and non-squamous) participants with confirmed MTAP loss will receive TNG456 at the identified RP2D(s) with abemaciclib",[13,14],{"label":32,"type":10,"description":33,"interventionNames":34},"GBM Combination Expansion","GBM participants with confirmed MTAP loss will receive TNG456 at the identified RP2D(s) with abemaciclib",[13,14],{"label":36,"type":10,"description":37,"interventionNames":38},"Tumor Agnostic Combination Expansion","Participants with specific tumor types with confirmed MTAP loss will receive TNG456 at the identified RP2D(s) with abemaciclib",[13,14],[40,46],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":45},"DRUG","TNG456","A selective PRMT5 inhibitor",[32,20,28,16,9,36,24],null,{"type":41,"name":47,"description":48,"armGroupLabels":49,"otherNames":50},"abemaciclib","A kinase inhibitor",[32,28,9,36],[51],"Verzenio",[53],{"name":54,"affiliation":5,"role":55},"Tab Cooney, MD","STUDY_DIRECTOR",[57],{"name":54,"role":58,"phone":59,"phoneExt":45,"email":60},"CONTACT","(857) 320-4899","clinicaltrials@tangotx.com",[62,80,93,105,117,130,143,156,169,182,194,203,216,229,242],{"facility":63,"status":64,"city":65,"state":66,"zip":67,"country":68,"countryCode":69,"cosmosGeoPoint":70,"geoPoint":75,"contacts":76},"Mayo Clinic Scottsdale","RECRUITING","Scottsdale","Arizona","85259-5452","United States","US",{"type":71,"coordinates":72},"Point",[73,74],-111.89903,33.50921,{"lat":74,"lon":73},[77],{"name":78,"role":79,"phone":45,"phoneExt":45,"email":45},"Mitesh Borad, MD","PRINCIPAL_INVESTIGATOR",{"facility":81,"status":64,"city":82,"state":83,"zip":84,"country":68,"countryCode":69,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"University of California, Irvine","Irvine","California","92686",{"type":71,"coordinates":86},[87,88],-117.82311,33.66946,{"lat":88,"lon":87},[91],{"name":92,"role":79,"phone":45,"phoneExt":45,"email":45},"Cathleen Park, MD",{"facility":94,"status":64,"city":95,"state":83,"zip":96,"country":68,"countryCode":69,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"University of California Los Angeles","Los Angeles","90995",{"type":71,"coordinates":98},[99,100],-118.24368,34.05223,{"lat":100,"lon":99},[103],{"name":104,"role":79,"phone":45,"phoneExt":45,"email":45},"Timothy Cloughesy, MD",{"facility":106,"status":64,"city":107,"state":83,"zip":108,"country":68,"countryCode":69,"cosmosGeoPoint":109,"geoPoint":113,"contacts":114},"University of California at San Francisco","San Francisco","94143-2202",{"type":71,"coordinates":110},[111,112],-122.41942,37.77493,{"lat":112,"lon":111},[115],{"name":116,"role":79,"phone":45,"phoneExt":45,"email":45},"Nicolas Butowski, MD",{"facility":118,"status":64,"city":119,"state":120,"zip":121,"country":68,"countryCode":69,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Sibley Memorial Hospital","Washington D.C.","District of Columbia","20016",{"type":71,"coordinates":123},[124,125],-77.03637,38.89511,{"lat":125,"lon":124},[128],{"name":129,"role":79,"phone":45,"phoneExt":45,"email":45},"Solmaz Sahebjam, MD",{"facility":131,"status":64,"city":132,"state":133,"zip":134,"country":68,"countryCode":69,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Mayo Clinic Jacksonville","Jacksonville","Florida","32224",{"type":71,"coordinates":136},[137,138],-81.65565,30.33218,{"lat":138,"lon":137},[141],{"name":142,"role":79,"phone":45,"phoneExt":45,"email":45},"Hani Babiker, MD",{"facility":144,"status":64,"city":145,"state":146,"zip":147,"country":68,"countryCode":69,"cosmosGeoPoint":148,"geoPoint":152,"contacts":153},"Northwestern Memorial Hospital","Chicago","Illinois","60611-2908",{"type":71,"coordinates":149},[150,151],-87.65005,41.85003,{"lat":151,"lon":150},[154],{"name":155,"role":79,"phone":45,"phoneExt":45,"email":45},"Ditte Primdahl, MD",{"facility":157,"status":64,"city":158,"state":159,"zip":160,"country":68,"countryCode":69,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Dana Farber Cancer Institute","Boston","Massachusetts","02215",{"type":71,"coordinates":162},[163,164],-71.05977,42.35843,{"lat":164,"lon":163},[167],{"name":168,"role":79,"phone":45,"phoneExt":45,"email":45},"Jia Luo, MD",{"facility":170,"status":64,"city":171,"state":172,"zip":173,"country":68,"countryCode":69,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"Mayo Clinic Cancer Center","Rochester","Minnesota","55905-0001",{"type":71,"coordinates":175},[176,177],-92.4699,44.02163,{"lat":177,"lon":176},[180],{"name":181,"role":79,"phone":45,"phoneExt":45,"email":45},"Kaushal Parikh, MD",{"facility":183,"status":64,"city":184,"state":184,"zip":185,"country":68,"countryCode":69,"cosmosGeoPoint":186,"geoPoint":190,"contacts":191},"NYU Langone Health","New York","10016",{"type":71,"coordinates":187},[188,189],-74.00597,40.71427,{"lat":189,"lon":188},[192],{"name":193,"role":79,"phone":45,"phoneExt":45,"email":45},"Salman Punekar, MD",{"facility":195,"status":64,"city":184,"state":184,"zip":196,"country":68,"countryCode":69,"cosmosGeoPoint":197,"geoPoint":199,"contacts":200},"Memorial Sloan Kettering Cancer Center","11065",{"type":71,"coordinates":198},[188,189],{"lat":189,"lon":188},[201],{"name":202,"role":79,"phone":45,"phoneExt":45,"email":45},"Lauren Schaff, MD",{"facility":204,"status":64,"city":205,"state":206,"zip":207,"country":68,"countryCode":69,"cosmosGeoPoint":208,"geoPoint":212,"contacts":213},"Ohio State University Comprehensive Cancer Center","Columbus","Ohio","43210",{"type":71,"coordinates":209},[210,211],-82.99879,39.96118,{"lat":211,"lon":210},[214],{"name":215,"role":79,"phone":45,"phoneExt":45,"email":45},"Dwight Owen, MD",{"facility":217,"status":64,"city":218,"state":219,"zip":220,"country":68,"countryCode":69,"cosmosGeoPoint":221,"geoPoint":225,"contacts":226},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":71,"coordinates":222},[223,224],-95.36327,29.76328,{"lat":224,"lon":223},[227],{"name":228,"role":79,"phone":45,"phoneExt":45,"email":45},"Jordi Rodon, MD",{"facility":230,"status":64,"city":231,"state":232,"zip":233,"country":68,"countryCode":69,"cosmosGeoPoint":234,"geoPoint":238,"contacts":239},"University of Utah, Huntsman Cancer Institute","Salt Lake City","Utah","84112-5500",{"type":71,"coordinates":235},[236,237],-111.89105,40.76078,{"lat":237,"lon":236},[240],{"name":241,"role":79,"phone":45,"phoneExt":45,"email":45},"Howard Coleman, MD",{"facility":243,"status":64,"city":244,"state":245,"zip":246,"country":68,"countryCode":69,"cosmosGeoPoint":247,"geoPoint":251,"contacts":252},"NEXT Virginia","Fairfax","Virginia","22031",{"type":71,"coordinates":248},[249,250],-77.30637,38.84622,{"lat":250,"lon":249},[253],{"name":254,"role":79,"phone":45,"phoneExt":45,"email":45},"Alexander Spira, MD, PhD",{"type":256,"investigatorFullName":45,"investigatorTitle":45,"investigatorAffiliation":45,"oldNameTitle":45,"oldOrganization":45},"SPONSOR",[258],{"name":259,"class":6},"Eli Lilly and Company","100578380","phase-1-safety-and-tolerability-of-tng456-alone-and-in-combination-with-abemaciclib-in-patients-with-solid-tumors-with-mtap-loss-100578380",false,"NCT06810544","Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","A Phase 1\u002F2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","Inclusion Criteria:\n\n* Has a tumor with a confirmed MTAP loss\n* Is ≥18 years of age at the time of signature of the main study ICF\n* Has had progression or an inadequate response to or is intolerant of the approved standard of care therapy, no standard of care therapy exists, or the investigator has determined that treatment with the standard of care therapy is not appropriate.\n* Is able to swallow tablets\n* Adequate Organ function\u002Freserve per local labs\n* Negative serum pregnancy test result at screening\n* Has an ECOG performance status score of 0 to 1\n* Has measurable disease based on RECIST v1.1 or a confirmed glioblastoma (IDH-wildtype) with radiographic evidence of disease progression or recurrence defined by RANO 2.0.\n* Has an ECOG performance score of 0 to 1 or for GBM has a Karnofsky performance status score ≥70.\n\nExclusion Criteria:\n\n* A female patient is who is pregnant or breastfeeding\n* Has impaired GI function or disease that may significantly alter the absorption of oral study treatment(s)\n* Has an active infection requiring systemic therapy\n* Has received prior treatment with a PRMT5 inhibitor or a MAT2A inhibitor\n* Patients in the expansion receiving the combination therapy that have received prior treatment with a CDK4\u002F6 inhibitor\n* Clinically relevant cardiovascular disease\n* Has a prior or ongoing clinically significant illness may affect the safety of the patient, impair the assessment of study results or compliance with the protocol","ALL","18 Years",{"count":270,"type":271},191,"ESTIMATED","INTERVENTIONAL",[274,275],"PHASE1","PHASE2","This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.",[278,279,280,281,282,283,284],"Non Small Cell Lung Cancer","Glioma Glioblastoma Multiforme","Glioma, Malignant","Solid Tumor","Non-Small Cell Adenocarcinoma","Lung Cancer","Brain Tumor",[286,287,288,47,289],"MTAP","PRMT5 inhibitor","CDK 4\u002F6","Tango","2026-04-10",{"date":292,"type":293},"2026-04-13","ACTUAL",{"date":295,"type":293},"2025-03-24",{"date":297,"type":271},"2027-09-30",{"name":5,"class":6},15]